A novel immunotherapy for the treatment of HPV+ tumors based on a chimeric Virus-like Drug Conjugate
News Category: Presentations
AACR 2023: Dr. Kines Presents cVDC Data
A novel chimeric virus-like drug conjugate for the potential treatment of HPV+ tumors
ARVO 2023: Dr. Ma Presents Preclinical Belzupacap Sarotalocan Data
The role of pigmentation in tumor treatment with virus-like drug conjugate belzupacap sarotalocan (AU-011) in an vitro and vivo model
Macula Society 2023: Dr. Kim Presents Phase 2 SC Safety Belzupacap Sarotalocan Data
A Phase 2 Trial of Belzupacap Sarotalocan (AU-011): An Investigational Targeted Therapy for Choroidal Melanoma via Suprachoroidal Administration
SUO 2022: Dr. Shore Presents Trial in Progress Phase I NMIBC Data
A Phase 1, Open-Label Trial to Determine Feasibility and Safety of Intramural Injection of Belzupacap Sarotalocan (AU-011) in Non-Muscle Invasive Bladder Cancer (NMIBC)
AAO 2022: Dr. Kim Presents Phase 2 SC Safety Belzupacap Sarotalocan Data
A Phase 2 Trial of Belzupacap Sarotalocan (AU-011), a First-in-Class Targeted Therapy for Choroidal Melanoma via Suprachoroidal Administration
ESMO 2022: Dr. Demirci Presents Phase 2 SC Safety Belzupacap Sarotalocan Data
A Phase 2 Trial of Belzupacap Sarotalocan (AU-011), an Investigational, Virus-Like Drug Conjugate (VDC) for the Treatment of Primary Indeterminate Lesions and Small Choroidal Melanoma (IL/CM) using Suprachoroidal Administration – (NCT04417530)
EURETINA 2022: Dr. Jager Presents Preclinical Belzupacap Sarotalocan Data
New Developments in Belzupacap Sarotalocan (AU-011), an Investigational Virus-Like Drug Conjugate (VDC) in Ocular Oncology
EURETINA 2022: Dr. Jager Presents Phase 1b/2 IVT and Phase 2 SC Belzupacap Sarotalocan Data
Clinical Evaluation of Belzupacap Sarotalocan (AU-011), a First-in-Class Targeted Therapy for Choroidal Melanoma with Intravitreal or Suprachoroidal Route of Administration
ISOO 2022: Educational Session Highlighting Retrospective Study of Belzupacap Sarotalocan versus Radiotherapy in Choroidal Melanoma
Topline Data from a Retrospective, Matched Case Study Evaluating Belzupacap Sarotalocan (AU-011) versus Plaque Radiotherapy, Supports the Value of a Vision Preserving Therapy for the Treatment of Patients with Early-Stage Choroidal Melanoma